61 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
damages, profits, and awards of whatever nature recovered by the Licensee for such infringement shall be treated as Net Sales subject to a deduction … shall previously have been informed of the confidential nature of the Confidential Information and shall have agreed to be bound by a legal
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
right of confidence or industrial property right of any nature whatsoever in any part of the world.
1.16
“Know-how” shall mean information, know-how … Schedule. However, it is understood by both Parties that the Services are of scientific in nature and that the Time Schedule is an estimate.
SITE VISITS
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
whatsoever in the nature of taxes, including income, gross receipts, profits, franchise, license, registration, capital stock, sales, use, value added, ad … into account, in addition to the fair market value of the Transferred Assets and any additional Buyer data and materials, the nature and extent
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of Common Stock to the former Tenet equityholders in accordance with the terms and conditions set forth in the Acquisition Agreement. The nature … of the transaction and the nature and amount of consideration received by Tenet’s equityholders are described in Item 2.01 of this Current Report on Form 8-K
8-K
EX-99.6
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
will be allocated to IPR&D based on the nature of the assets and liabilities acquired.
3. Transaction Accounting Adjustments
Adjustments included in the column
8-K
EX-10.1
1dk6cygnb580kb
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
2zl9nfh5uvbzu4q3xkk1
4 Jun 24
Proxy related to merger
8:00am
PREM14A
f6v560hqr
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
zgl8lie7d7qqcoeq5d
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
2fsae44 t2m3m
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
u8qtzaogwq9t4
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
ocdj9sp y3ow
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
9rz6 33ej
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
o6ytruhhho31d 81
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
ljwq6n3mfr0
18 Mar 24
Other Events
6:34pm